阿尔茨海默病的有症状和非淀粉样蛋白/tau 相关的药物治疗。
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
机构信息
University of California, San Diego, California 92093, USA.
出版信息
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006395. doi: 10.1101/cshperspect.a006395.
Abstract
In this work we consider marketed drugs for Alzheimer disease (AD) including acetylcholinesterase inhibitors (AChE-Is) and antiglutamatergic treatment involving the N-methyl-d-aspartate (NMDA) receptor. We discuss medications and substances available for use as cognitive enhancers that are not approved for AD or cognitive impairment, and other neurotransmitter-related therapies in development or currently being researched. We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau.
摘要
在这项工作中，我们考虑了用于治疗阿尔茨海默病（AD）的已上市药物，包括乙酰胆碱酯酶抑制剂（AChE-Is）和涉及 N-甲基-D-天冬氨酸（NMDA）受体的抗谷氨酸治疗。我们讨论了可作为认知增强剂使用的、未获 AD 或认知障碍批准的药物和物质，以及其他正在开发或正在研究中的与神经递质相关的治疗方法。我们还回顾了通过与淀粉样蛋白或 tau 无关的机制来减缓疾病进展的潜在治疗方法。
相似文献
1
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.阿尔茨海默病的有症状和非淀粉样蛋白/tau 相关的药物治疗。
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006395. doi: 10.1101/cshperspect.a006395.
2
Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.用于治疗阿尔茨海默病的药物的药效学、药代动力学和药物遗传学方面。
Clin Pharmacokinet. 2013 Apr;52(4):225-41. doi: 10.1007/s40262-013-0038-9.
3
4
[Mechanisms of action of Alzheimer medications].[阿尔茨海默病药物的作用机制]
Duodecim. 2003;119(20):1959-66.
5
Pharmacologic treatment options in Alzheimer's disease: optimizing disease management.阿尔茨海默病的药物治疗选择：优化疾病管理
J Am Acad Nurse Pract. 2005 Mar;Suppl:5-7.
6
[Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions].基于胆碱能假说的阿尔茨海默病治疗方法的发展——现状与未来方向
Rinsho Shinkeigaku. 2013;53(11):1036-8. doi: 10.5692/clinicalneurol.53.1036.
7
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.多奈哌齐、加兰他敏、卡巴拉汀和美金刚治疗阿尔茨海默病的疗效与安全性：一项系统评价和荟萃分析。
J Alzheimers Dis. 2014;41(2):615-31. doi: 10.3233/JAD-132690.
8
Pharmacologic management of Alzheimer disease.阿尔茨海默病的药物治疗
J Neurosci Nurs. 2008 Feb;40(1):55-9. doi: 10.1097/01376517-200802000-00009.
9
Understanding the latest advances in pharmacologic interventions for Alzheimer's disease.了解阿尔茨海默病药物干预的最新进展。
CNS Spectr. 2004 Jul;9(7 Suppl 5):24-8. doi: 10.1017/s1092852900024780.
10
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.多奈哌齐、加兰他敏、利伐斯的明和美金刚治疗阿尔茨海默病的有效性和成本效果（技术评估第 111 号回顾）：系统评价和经济模型。
Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210.
引用本文的文献
1
Pharmacogenomics for neurodegenerative disorders - a focused review.神经退行性疾病的药物基因组学——一篇聚焦综述。
Front Pharmacol. 2024 Dec 20;15:1478964. doi: 10.3389/fphar.2024.1478964. eCollection 2024.
2
Sex Differences in Alzheimer's Disease.阿尔茨海默病的性别差异。
Neurol Clin. 2023 May;41(2):343-358. doi: 10.1016/j.ncl.2023.01.001.
3
Effect of Treadmill Exercise and Trans-Cinnamaldehyde against d-Galactose- and Aluminum Chloride-Induced Cognitive Dysfunction in Mice.跑步机运动和反式肉桂醛对d-半乳糖和氯化铝诱导的小鼠认知功能障碍的影响。
Brain Sci. 2020 Oct 29;10(11):793. doi: 10.3390/brainsci10110793.
4
Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future?提高乙酰胆碱酯酶抑制剂在阿尔茨海默病中的神经退行性保护作用：不可逆抑制剂是未来的趋势吗？
Int J Mol Sci. 2020 May 13;21(10):3438. doi: 10.3390/ijms21103438.
5
Epidemiology and Risk Factors of Alzheimer's Disease in Iran: A Systematic Review.伊朗阿尔茨海默病的流行病学与风险因素：一项系统综述
Iran J Public Health. 2019 Dec;48(12):2133-2139.
6
Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.淀粉样蛋白正电子发射断层扫描与轻度认知障碍或痴呆的医疗保险受益人的临床管理变化的相关性。
JAMA. 2019 Apr 2;321(13):1286-1294. doi: 10.1001/jama.2019.2000.
7
Late-onset Alzheimer Disease.晚发性阿尔茨海默病
Continuum (Minneap Minn). 2019 Feb;25(1):14-33. doi: 10.1212/CON.0000000000000700.
8
Hydroxyurea attenuates oxidative, metabolic, and excitotoxic stress in rat hippocampal neurons and improves spatial memory in a mouse model of Alzheimer's disease.羟脲可减轻大鼠海马神经元的氧化应激、代谢应激和兴奋毒性应激，并改善阿尔茨海默病小鼠模型的空间记忆。
Neurobiol Aging. 2018 Dec;72:121-133. doi: 10.1016/j.neurobiolaging.2018.08.021. Epub 2018 Aug 29.
9
Characterization of Hit Compounds Identified from High-throughput Screening for their Effect on Blood-brain Barrier Integrity and Amyloid-β Clearance: In Vitro and In Vivo Studies.高通量筛选血脑屏障完整性和淀粉样β清除效果的命中化合物的特征：体外和体内研究。
Neuroscience. 2018 May 21;379:269-280. doi: 10.1016/j.neuroscience.2018.03.028. Epub 2018 Mar 26.
10
Markers of Alzheimer's Disease in Primary Visual Cortex in Normal Aging in Mice.阿尔茨海默病在正常衰老小鼠初级视觉皮层中的标志物。
Biomed Res Int. 2017;2017:3706018. doi: 10.1155/2017/3706018. Epub 2017 Sep 12.
本文引用的文献
1
Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.经鼻胰岛素治疗阿尔茨海默病和遗忘型轻度认知障碍：一项试点临床试验。
Arch Neurol. 2012 Jan;69(1):29-38. doi: 10.1001/archneurol.2011.233. Epub 2011 Sep 12.
2
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.阿尔茨海默病所致轻度认知障碍的诊断：美国国家老龄化研究所-阿尔茨海默病协会诊断指南工作组的建议。
Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.
3
A phase II trial of huperzine A in mild to moderate Alzheimer disease.一项石杉碱甲治疗轻中度阿尔茨海默病的 II 期临床试验。
Neurology. 2011 Apr 19;76(16):1389-94. doi: 10.1212/WNL.0b013e318216eb7b.
4
Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative.阿尔茨海默病神经影像倡议中患者使用胆碱酯酶抑制剂和美金刚的治疗情况。
Arch Neurol. 2011 Jan;68(1):58-66. doi: 10.1001/archneurol.2010.343.
5
PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease.PF-04494700，一种晚期糖基化终产物（RAGE）受体的口服抑制剂，用于治疗阿尔茨海默病。
Alzheimer Dis Assoc Disord. 2011 Jul-Sep;25(3):206-12. doi: 10.1097/WAD.0b013e318204b550.
6
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.二十二碳六烯酸补充剂与阿尔茨海默病认知能力下降：一项随机试验。
JAMA. 2010 Nov 3;304(17):1903-11. doi: 10.1001/jama.2010.1510.
7
Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.B 族维生素降低同型半胱氨酸可减缓轻度认知障碍患者脑萎缩加速的速度：一项随机对照试验。
PLoS One. 2010 Sep 8;5(9):e12244. doi: 10.1371/journal.pone.0012244.
8
A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease.吡格列酮治疗阿尔茨海默病患者安全性的随机试点临床试验。
Arch Neurol. 2011 Jan;68(1):45-50. doi: 10.1001/archneurol.2010.229. Epub 2010 Sep 13.
9
Dimebon disappointment.盐酸美金刚胺令人失望。
Alzheimers Res Ther. 2010 Sep 13;2(5):25. doi: 10.1186/alzrt49.
10
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.罗格列酮单药治疗轻中度阿尔茨海默病的随机、双盲、安慰剂对照 III 期研究结果。
Dement Geriatr Cogn Disord. 2010;30(2):131-46. doi: 10.1159/000318845. Epub 2010 Aug 21.
Zotero 插件